| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2024 | Jul 1, 2024 | Gain Therapeutics, Inc. | Director | Buy | 86.3 | +17,000 | 5.91% | ✗ | $20.7K |
| May 25, 2022 | May 27, 2022 | Gain Therapeutics, Inc. | CEO | Buy | 77.5 | +2,482 | 1.08% | ✗ | $6.4K |
| May 19, 2022 | May 23, 2022 | Gain Therapeutics, Inc. | CEO | Buy | 83.8 | +13,256 | 3.14% | ✗ | $37K |
| Aug 16, 2021 | Apr 21, 2022 | Gain Therapeutics, Inc. | CEO | Buy | 78.8 | +4,922 | 2.32% | ✗ | $38.7K |
| Jun 8, 2018 | Jun 11, 2018 | ADMA BIOLOGICS, INC. | Director | Buy | 91.3 | +5,230 | 16.71% | ✗ | $25K |
| Nov 9, 2017 | Nov 13, 2017 | ADMA BIOLOGICS, INC. | Director | Buy | 95.0 | +25,000 | 396.83% | ✗ | $53.8K |
| Apr 13, 2016 | Apr 15, 2016 | Altimmune, Inc. | Director | Sell | 7.5 | -329,354 | -31.47% | ✓ | $724.6K |
| Apr 7, 2016 | Apr 11, 2016 | Altimmune, Inc. | Director | Sell | 41.3 | -11,767 | -3.13% | ✓ | $25.9K |
| Mar 13, 2015 | Mar 17, 2015 | ADMA BIOLOGICS, INC. | Director | Buy | 91.3 | +3,500 | 100.00% | ✗ | $27.6K |
| Nov 10, 2011 | Nov 14, 2011 | Altimmune, Inc. | CEO | Buy | 86.3 | +10,000 | 8.04% | ✗ | $15K |
| Mar 23, 2010 | May 12, 2011 | Altimmune, Inc. | Officer | Sell | 26.3 | -10,500 | -9.56% | ✗ | $35.7K |
| Jan 21, 2011 | Jan 25, 2011 | Altimmune, Inc. | Officer | Sell | 26.3 | -3,057 | -2.71% | ✗ | $10.5K |
| Jun 17, 2010 | Jun 21, 2010 | Altimmune, Inc. | CEO | Buy | 91.3 | +10,000 | 16.51% | ✗ | $15.8K |